Caterina De Barba
Padova, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study.
Journal: Advances in therapy
Published: February 11, 2026
The microbiota-brain connection in neurological diseases: the ubiquitous short-chain fatty acids.
Journal: Minerva gastroenterology
Published: September 02, 2025
Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study.
Journal: Journal of clinical medicine
Published: August 27, 2025
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study.
Journal: Intestinal research
Published: April 29, 2025
Recent developments in managing luminal microbial ecology in patients with inflammatory bowel disease: from evidence to microbiome-based diagnostic and personalized therapy.
Journal: Expert review of gastroenterology & hepatology
Published: April 18, 2025
Machine learning identifies a distinct microbiota signature in immune checkpoint inhibitor colitis compared with inflammatory bowel disease.
Journal: The oncologist
Published: April 10, 2025
Advancing therapeutic frontiers: a pipeline of novel drugs for luminal and perianal Crohn's disease management.
Journal: Therapeutic advances in gastroenterology
Published: July 12, 2024
Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations.
Journal: Clinical and experimental gastroenterology
Published: June 03, 2024
Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications.
Journal: Life (Basel, Switzerland)
Published: March 25, 2024
Showing 1-9 of 9
Last Updated: 09/26/2026